GlassScriptPhysician profile
Dhanvendran Ramar
NPI 1316269640
$2,761.03
in general payments reported to CMS, 2019-2025
26 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $895 · 2020: $327 · 2022: $105 · 2023: $790 · 2024: $370 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $410.86 | 2019-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $287.40 | 2019-2023 | Rexulti, Abilify Asimtufii, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $270.64 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $255.68 | 2022-2024 | Caplyta |
| Abbvie INC. | $198.79 | 2023 | |
| Lundbeck LLC | $186.32 | 2019-2024 | Rexulti |
| Axsome Therapeutics, INC. | $152.48 | 2023-2024 | Auvelity |
| Allergan, INC. | $148.51 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $118.71 | 2019-2023 | Invega, Invega Trinza, Spravato |
| Sunovion Pharmaceuticals INC. | $111.63 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $102.79 | 2019-2024 | Ingrezza |
| Tris Pharma INC | $88.24 | 2019-2023 | Dyanavel Xr |
| Corium, LLC | $85.77 | 2022-2024 | Azstarys |
| Shire North American Group INC | $49.42 | 2019 | |
| Almatica Pharma LLC | $44.82 | 2023 | Loreev Xr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $42.56 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $40.14 | 2019-2023 | Jornay Pm |
| Bausch Health US, LLC | $31.67 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.13 | 2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $18.56 | 2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $18.41 | 2020 | |
| Indivior INC. | $17.50 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.74 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.96 | 2019 | |
| Sage Therapeutics, LLC | $14.95 | 2024 | |
| Vertical Pharmaceuticals, LLC | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhanvendran Ramar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.